amantadine has been researched along with methyldopa in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (35.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cohen, MR | 1 |
| Marsden, CD; Mindham, RH; Parkes, JD | 1 |
| Feigenson, JS; McDowell, FH; Sweet, RD | 1 |
| Calne, DB; Reid, JL | 1 |
| Duvoisin, RC; Yahr, MD | 1 |
| Calne, DB; Hilson, A; Rao, SK; Vakil, SD | 1 |
4 review(s) available for amantadine and methyldopa
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Antiparkinsonian drugs: pharmacological and therapeutic aspects.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Amantadine; Amphetamine; Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Carboxy-Lyases; Dihydroxyphenylalanine; Dopamine; Histamine H1 Antagonists; Humans; Mental Disorders; Methyldopa; Movement Disorders; Norepinephrine; Parasympatholytics; Serotonin; Synaptic Transmission | 1972 |
Drug therapy of parkinsonism.
Topics: Amantadine; Amitriptyline; Amphetamine; Antiparkinson Agents; Dihydroxyphenylalanine; Drug Antagonism; Drug Synergism; Humans; Imipramine; Methyldopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease; Phenothiazines | 1972 |
Augmenting the action of levodopa.
Topics: Amantadine; Antacids; Apomorphine; Carboxy-Lyases; Catechol O-Methyltransferase Inhibitors; Dihydroxyphenylalanine; Dopamine beta-Hydroxylase; Drug Synergism; Humans; Methyldopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease | 1972 |
1 trial(s) available for amantadine and methyldopa
| Article | Year |
|---|---|
Psychiatric symptoms during l-dopa therapy for Parkinson's disease and their relationship to physical disability.
Topics: Aged; Amantadine; Carbidopa; Clinical Trials as Topic; Depression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Interview, Psychological; Levodopa; Male; Mental Status Schedule; Methyldopa; Middle Aged; Parkinson Disease; Placebos; Recurrence; Trihexyphenidyl | 1976 |
12 other study(ies) available for amantadine and methyldopa
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Amantadine and alpha-methyldopa: effects and interactions.
Topics: Amantadine; Drug Therapy, Combination; Humans; Methyldopa; Psychoses, Substance-Induced | 1979 |
Piribedil: its synergistic effect in multidrug regimens for parkinsonism.
Topics: Aged; Amantadine; Drug Synergism; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Methyldopa; Middle Aged; Movement Disorders; Parasympatholytics; Parkinson Disease; Piperazines; Piribedil | 1976 |